In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS

 

Prognostic value of regional myocardial flow reserve derived from 13N-ammonia myocardial perfusion positron emission tomography in patients without known coronary artery disease.

Session Poster session I

Speaker Elia von Felten

Congress : ICNC, Nuclear Cardiology & Cardiac CT 2019

  • Topic : imaging
  • Sub-topic : Positron Emission Tomography (PET)
  • Session type : Poster Session
  • FP Number : P158

Authors : E Von Felten (Zurich,CH), D Patriki (Zurich,CH), DC Benz (Zurich,CH), J Baehler (Zurich,CH), AA Giannopoulos (Zurich,CH), G Benetos (Zurich,CH), M Messerli (Zurich,CH), AP Pazhenkottil (Zurich,CH), C Graeni (Zurich,CH), C Gebhard (Zurich,CH), TA Fuchs (Zurich,CH), PA Kaufmann (Zurich,CH), RR Buechel (Zurich,CH)

Authors:
E Von Felten1 , D Patriki1 , DC Benz1 , J Baehler1 , AA Giannopoulos2 , G Benetos1 , M Messerli1 , AP Pazhenkottil1 , C Graeni1 , C Gebhard1 , TA Fuchs1 , PA Kaufmann1 , RR Buechel1 , 1University of Zurich, Department of Nuclear Medicine - Zurich - Switzerland , 2University Hospital Zurich, Department of Cardiology - Zurich - Switzerland ,

Citation:

Background

The prognostic value of global myocardial flow reserve (MFR) is well established. However, only limited data exist on the value of regional myocardial reduction myocardial flow reserve.

Purpose

The goal of this study was to determine the impact of regional variations of MFR in patients without known coronary artery disease.

Methods

We retrospectively included 146 consecutive patients without known coronary artery disease (CAD) who underwent clinically indicated 13N-ammonia myocardial perfusion positron emission tomography (PET) at our institution. Global and regional MFR, based on a 17-segment model were calculated. Patients were classified into three groups. Group 1: Patients with preserved global and regional MFR. Group 2: Patients with preserved global but reduced regional MFR (i.e. = 3 adjacent segments with MFR < 2.12 ml/min/g). Group 3: Patients with reduced global MFR (i.e. < 2 ml/min/g). Follow-up was obtained regarding a composite endpoint including all-cause death, nonfatal myocardial infarction, and late revascularization (i.e. = 60 days after the PET scan). We performed Kaplan-Meier and Cox regression analysis.

Results

During a median follow-up of 47±36 months, a total of 24 events (15 deaths, 2 nonfatal myocardial infarctions, 7 late revascularizations) occurred. Annual event rate was 1.43% in group 1, 4.76% in group 2, and 3.11% in group 3. Kaplan-Meier analysis showed a significant difference between these groups (log Rank p=0.046). While group 1 differed significantly from group 2 (log Rank p=0.013) and group 3 (log Rank p=0.013), there was no difference between Group 2 and 3. Multivariate Cox regression revealed a reduced regional MFR as an independent predictor for future cardiac events (p=0.011).

Conclusion

In patients without known CAD global and regional MFR impact prognosis. However, in the present study, only regional MFR was found to be an independent predictor of adverse cardiovascular outcome.

This content is currently on FREE ACCESS

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are